Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AZ/Fujifilm Develop Chemoradiotherapy Database for Lung Cancer
April 10, 2024
- Hypertension Therapy App Might Reduce Use of Antihypertensives: CureApp
April 10, 2024
- Otsuka/Lundbeck Seek PTSD Nod for Rexulti in US
April 10, 2024
- US FDA Grants Orphan Exclusivity for ALS Drug Radicava ORS
April 10, 2024
- R&D Jobs Make Up 40% of Pharma New Grads Hires This Spring, Sales Reps Only 20%: Poll
April 9, 2024
- Toray Nets Positive Preclinical Data in Polymer-Conjugated Cancer Drug
April 9, 2024
- Renalys Submits IND for Japan PIII Study of IgA Nephropathy Drug
April 9, 2024
- Janssen Files Amivantamab Plus Lazertinib for NSCLC in Japan
April 9, 2024
- Enhertu Nabs Pan-Tumor Indication in US: Daiichi Sankyo
April 9, 2024
- GSK Japan Shooting for 80% Goal for Paid Paternity Leave in 2024
April 8, 2024
- Otsuka, Verily Join Forces to Run Mental Health Registry
April 8, 2024
- Japan Ethical Drug Sales Zoom 12.1% in February: Crecon
April 8, 2024
- Keytruda Tops Japan Sales List for 6th Month in March: Encise
April 8, 2024
- Kyowa Kirin Hopes Amgen-Partnered Eczema Drug to Rival or Even Eclipse Crysvita in Sales: CEO
April 5, 2024
- Rohto, Mitsui to Buy Singapore’s Chinese Medicine Firm for SGD800 Million
April 5, 2024
- Nippon Shinyaku, MiNA Therapeutics Join Hands in Rare CNS Disorders
April 5, 2024
- Healios Snaps Up Assets after Athersys’ Bankruptcy Filing
April 5, 2024
- Tarlige Winner in February GP Rep Promotion Rankings
April 4, 2024
- Taisho’s Positive PIII Data Set Stage for Japan Filing of Insomnia Med
April 4, 2024
- FDA OKs First Digital Therapeutic App for Depression: Otsuka
April 4, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…